


ter and dioxane mixture to the corresponding pyridinium ylides. The ylides provided the substituted N-(pyridyl/phenyl) carbonyl/sulfonylamino-1,2,3,6-tetrahydropyridines when reduced using sodium borohydride in ethanol at ice-bath temperature. The anti-inflammatory activities of these tetrahydropyridines were determined using the rat paw edema assay with Indomethacin as the reference compound. Inhibition of the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes were also conducted. Several analogs were found to possess significant anti-inflammatory activities with varying degrees of COX-2/COX-1 ratios. The investigation was supported by a grant from the US National Institutes of Health (NIH), GM 08111 and RR 03020.

421

#### Relationships between DNA alkylation, perturbation of the cell cycle and cytotoxicity in a series of benzoacronycine derivatives

A. Pierre<sup>1</sup>, S. Leonce<sup>1</sup>, C. Bailly<sup>2</sup>, M. Koch<sup>3</sup>, F. Tillequin<sup>3</sup>, B. Pfeiffer<sup>1</sup>, J.A. Hickman<sup>1</sup>. <sup>1</sup>Institut de Recherches Servier, Cancer research, Suresnes, France; <sup>2</sup>INSERM U524 and Centre Oscar Lambret, Lille, France; <sup>3</sup>Universite Rene Descartes, Paris, France

Due to outstanding antitumor properties in orthotopic models of human solid tumors, the synthetic benzoacronycine derivative S23906-1 has been selected for advanced preclinical development. This compound was recently shown to bind covalently to DNA in the minor groove and alkylate the guanine residues at the N2 position. This unusual property, coupled with uncommon cell cycle perturbations characterized by a cell cycle arrest in the S or G2+M phases, raises the question regarding the precise molecular mechanism underlying the antitumor properties of S23906-1. To address this question, a resistant cell line was established by stepwise exposure of KB-3-1 epidermoid carcinoma cells to S23906-1. The resistant KB/S23-500 line, which does not display the classical MDR phenotype, was used to screen the derivatives. A set of selected compounds was studied for their i) cytotoxic properties in L1210, KB-3-1 and KB/S23-500 cells in culture measured by the MMT assay, ii) perturbation of cell cycle measured by flow cytometry and iii) *in vitro* DNA alkylation as determined by reduction of the electrophoretic mobility of reacted DNA.



The most cytotoxic compounds possessed a methoxy group at the C3 position and at least one leaving group at the C1 and C2 positions. These cytotoxic derivatives formed covalent adducts with DNA *in vitro*. The resistant KB/S23-500 cells were cross resistant to the compounds that induced an arrest in S and G2+M phases, in contrast to compounds arresting cells only in G2+M phases. A tight correlation between cytotoxicity, arrest in S phase, cross resistance of the KB/S23-500 cell line and DNA alkylation was thus observed for compounds with a good leaving group. These observations strongly suggest that DNA is actually an important target for this class of compounds.

422

#### 2-Benzimidazolylhydrazones derived from alpha-(N)-acyl heteroaromatics: RNA synthesis inhibitors with camptothecin-like activity

J. Easmon<sup>1</sup>, G. Peurstinger<sup>1</sup>, A. Schmidt<sup>1</sup>, J. Hofmann<sup>2</sup>, G. Heinisch<sup>1</sup>, Z.L. Liao<sup>3</sup>, Y. Pommier<sup>3</sup>. <sup>1</sup>University of Innsbruck, Pharmaceutical Chemistry Department, Innsbruck, Austria; <sup>2</sup>University of Innsbruck, Institute of Medical Chemistry and Biochemistry, Innsbruck, Austria; <sup>3</sup>Center for Cancer Research, NCI, NIH, USA

Recently we have shown that replacement of the thiocarbamoyl moiety in 2-acetylpyridine thiosemicarbazone (TSC) by a 2-benzothiazole (BZT) ring results in compounds with high cytotoxic activity (factor ~ 10) [J. Easmon et al. Eur. J. Med. Chem. 1997, 32, 397-408]. In a classical bioisosteric follow up studies, hydrazones bearing a 2-benzimidazolyl moiety had been synthesised and their antiproliferative activity evaluated *in vitro* against a panel

of human tumor cell lines using the MMT assay. For this class of agents, hydrazone derivatives of 2-acetylpyridines inhibited cell proliferation at lower concentrations (IC<sub>50</sub> = 0.006-1.36 μM) compared to the acetyl diazine and quinoline derived compounds (IC<sub>50</sub> = 0.21-3.37 μM). Moreover, the novel hydrazones are not substrate for the MDR efflux system and do not show cross resistance to hydroxyurea resistant KB cells. However, in the 2 day NCI *in vitro* assay both types of compounds were found to be equipotent with a mean GI50 of -7.27 to -6.44 for the acetylpyridine derived compounds and a mean GI50 of -7.31 to -5.71 for the acetyl diazine derived hydrazones. Based on the *in vitro* assay results, several of the compounds were then evaluated in the *in vivo* Hollow Fiber Assay. Compounds fulfilling one or more of the several criteria used to identify positive result are EPH 97-NSC 703101 (IP: 6, SC: 8), EPH 241-NSC 703106 (IP: 6, SC: 8), EPH 307-NSC 720194 (IP: 12, SC: 0), and EPH 316-NSC 720195 (IP: 12, SC: 8) with no net cell kill observed. In a study of the effects of the compounds on macromolecular synthesis in L1210 lymphoid leukemia cells, RNA synthesis was preferentially inhibited (e.g. EHP 61, IC<sub>50</sub> < 5 μM) whilst DNA and protein synthesis are not affected (IC<sub>50</sub> > 100 μM). Using EPH 103 (NSC 703104) and other analogues as a seed in the COMPARE analysis, a positive correlation to camptothecin and analogues was obtained with a PCC of 0.75 - 0.60. The hydrazone derivatives have been tested in topoisomerase I-deficient cells. Preliminary results suggest that resistance to topoisomerase I-deficient cells and this would be consistent with topoisomerase-I targeting. The synthesis, structure activity-relationships, and biochemical studies relating to this class of compounds will be presented. Financial support was provided in part by the Austrian Science Foundation (FWF), project No. P12384-MOB.

423

#### Novel pteridine-based inhibitors of cAMP phosphodiesterases: promising antineoplastic agents

K. Merz<sup>1</sup>, N. Graf v. Keyserlingk<sup>2</sup>, S. Vatter<sup>1</sup>, M. Habermeyer<sup>1</sup>, G. Eisenbrand<sup>1</sup>. <sup>1</sup>University of Kaiserslautern, Department of Chemistry, Division of Food Chemistry and Environmental Toxicology; <sup>2</sup>Faustus Forschungs Compagnie Translational Cancer R, Leipzig, Germany

The second messenger cAMP is involved in a multitude of cellular processes, including for example cell growth and cell differentiation. The intracellular level of cAMP is regulated by adenylate cyclases and cAMP phosphodiesterases (PDEs). Many human and non human tumor cells exhibit markedly enhanced cAMP phosphodiesterase activity, concomitant with low intracellular cAMP levels. This suggests that inhibition of cAMP PDE might be exploitable for antitumor treatment. Specific amine substituted pteridines have been identified as highly potent PDE inhibitors, with preference for the PDE4 isoenzyme family, the predominant isoenzyme family in many tumors. This had been demonstrated previously for pteridine derivatives bearing different substituents in the 4- and 7-position of the bicyclic core, showing efficient growth inhibition in various tumor cell lines. Effective intracellular inhibition of PDE activity was achieved together with enhanced cAMP levels and subsequent induction of apoptosis. In the course of our structure-activity-studies we identified pteridine derivatives with potent PDE4 inhibitory properties, bearing identical amino substituents in 4- and 7- position of the pteridine ring system. These compounds were found to be more easily accessible by chemical synthesis. Novel compounds were tested in cell lines expressing different levels of total PDE-activity, with PDE4 representing the highest cAMP hydrolyzing activity. Efficient growth inhibitory activity in different tumor cell lines (IC<sub>50</sub> down to 1 mM) was observed. The project was supported by EFRE of the EU and by funds from the Freistaat Sachsen (P-Nr: 6306).

424

#### Synthesis and biological evaluation of phosphoramidate mustard (PM) prodrugs

D. Farquhar<sup>1</sup>, C. Ballatore<sup>1</sup>, J. Nelson<sup>2</sup>, B. Andersson<sup>3</sup>. <sup>1</sup>University of Texas M.D. Anderson Cancer Center, Experimental Therapeutics, Houston, USA; <sup>2</sup>University of Texas M.D. Anderson Cancer Center, Education, Houston, USA; <sup>3</sup>University of Texas M.D. Anderson Cancer Center, Bone Marrow Transplantation, Houston, USA

Cyclophosphamide and ifosfamide are bifunctional alkylating agents used for the chemotherapeutic management of many common human malignancies. These agents are not active in their own right but are oxidatively biotransformed, mainly in the liver, by cytochrome P-450 dependent mixed-function oxidases to unstable intermediates that are believed to transport the ultimate active metabolites, phosphoramidate mustards (PM's), into cells.